| Literature DB >> 33026657 |
Aldo Pezzuto1, Antonella Tammaro2, Giuseppe Tonini3, Massimo Ciccozzi4.
Abstract
Entities:
Keywords: COPD; SARS-Cov-2; comorbidities; survival
Mesh:
Year: 2020 PMID: 33026657 PMCID: PMC7675494 DOI: 10.1002/jmv.26585
Source DB: PubMed Journal: J Med Virol ISSN: 0146-6615 Impact factor: 20.693
Differences between Group 2 admitted to the internal medicine unit and Group 1 admitted to the intensive care unit
| G2 | G1 |
| |
|---|---|---|---|
| Age | 63 (45–56) | 60 (52–65) | .10 |
| Pack‐year | 35.0 (32–40) | 36.5 (35–40) | .17 |
| Former smokers % | 45 | 54 | .04 |
| Diabetes % | 50 | 53 | .15 |
| COPD % | 50 | 65 | .05 |
| Flu vaccination % | 35 | 36 | .20 |
| Complicated pneumonia % | 58 | 66 | .03 |
| Lymphopenia % | 35 | 38 | .10 |
| Basal PaO2 mmHg | 55.1 (52.3–61.1) | 50.4 (47.2–54.5) | .04 |
| Hypertension % | 38 | 42% | .05 |
Note: Mann–Whitney or Fisher's exact test as appropriate. Data expressed as median and interquartile range. G2 internal medicine unit. G1 intensive care unit. Values expressed as percentage indicating percentage of the whole population for each group.
Abbreviation: COPD, chronic obstructive pulmonary disease.
Covariates associated with survival
|
|
|
| |
|---|---|---|---|
| COPD | 2.96 | 1.1–5.0 | .02 |
| Diabetes | 1.35 | 0.18–5.47 | .5 |
| Age | 1.02 | 0.97–1.07 | .9 |
| Lymphopenia | 1.16 | 0.46–2.88 | .7 |
| Hypertension | 1.14 | 0.49–2.62 | .7 |
| Flu vaccination | 0.95 | 0.65–1.17 | .10 |
| Bilateral pneumonia | 0.79 | 0.20–3.0 | .79 |
| Pack‐years | 1.55 | 0.90–3.50 | .05 |
Note: Cox proportional hazard regression.
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease.
Figure 1Differences in overall survival between Group 1 (intensive care unit) and Group 2 (internal medicine unit) (HR 2.8; p < .0001)